Potential Biomarker in Metastatic Renal Cell Carcinoma
Researchers are studying a potential biomarker that may predict clinical benefit to the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor sunitinib in patients with metastatic renal cell carcinoma. Patients who carry the single-nucleotide polymorphism—KDR rs34231037—variant seem to respond better to sunitinib than do wild-type patients, according to a study by Cristina Rodriguez-Antona, PhD, of the Spanish National Cancer Research Centre, Madrid, Spain, and colleagues published in Pharmacogenetics and Genomics.
They assessed the clinical data and DNA available from an international series of 276 patients with metastatic clear cell renal cell carcinoma. Among patients with clinical benefit during sunitinib treatment, G-allele carriers were overrepresented, compared with those who were refractory to treatment with sunitinib (odds ratio = 3.78; P=.047, multivariable analysis).
In addition to the predictive potential of this biomarker in terms of response to treatment with sunitinib, the single-nucleotide polymorphism may also play a future role in identifying patients with successful tumor downstaging under anti-VEGFR therapy, the investigators concluded.